Analyst Research Report Snapshot

Title:

BIOLINERX - EXPLOITING IP FROM THE LAND OF MILK AND HONEY

Price:

$10.00

Provider:

Edison Investment Research

Date:

09 Dec 2013

Pages:

16

Type:

AcrobatPDF

Companies referenced:

BLRX.TA SASY.PA

Available for Immediate Download
Summary:

BioLineRx is entering a catalyst-rich phase over the next 12 months, which will see early clinical data from studies of two internal R&D projects, BL-8040 (acute myeloid leukaemia) and BL-8020 (HCV). Pivotal data should also emerge in 2014 from BioLineRx’s lead partnered programme, BL-1040, for the prevention of cardiac remodelling following acute myocardial infarction and from BL-5010 for benign skin lesions. Ahead of these key catalysts, we value BioLineRx at $210m, equivalent to $8.9/ADR (basic) or $7.9/ADR (fully diluted).

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.